Amyotrophic Lateral Sclerosis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | Biogen, Ionis, AbbVie, Genuv, Kadimastem, Cytokinetics, MediciNova, Retrotope, Sanofi, Novartis, Helixmith

DelveInsight's "Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Amyotrophic Lateral Sclerosis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Amyotrophic Lateral Sclerosis (ALS) Market: An Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Amyotrophic Lateral Sclerosis belongs to a broader group of disorders known as motor neuron diseases, which are caused by the gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to the muscles throughout the body.

Amyotrophic Lateral Sclerosis can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. The terms familial and genetic mean that this type of Amyotrophic Lateral Sclerosis is inherited. In families who have genetic Amyotrophic Lateral Sclerosis, there is an up to 50% chance that each child will inherit the gene and develop the disease.

No one test can provide a definitive diagnosis of Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis is primarily diagnosed based on a detailed history of the symptoms and signs observed by a physician during physical examination along with a series of tests to rule out other mimicking diseases. However, the presence of upper and lower motor neuron symptoms strongly suggests the presence of the disease. Tests that may help diagnose Amyotrophic Lateral Sclerosis are electromyography (EMG), nerve conduction study (NCS), and magnetic resonance imaging (MRI).

Further tests to rule out other conditions may include blood and urine tests and a muscle biopsy. Medical problems that can produce similar symptoms to Amyotrophic Lateral Sclerosis, such as HIV, Lyme disease, multiple sclerosis (MS), the poliovirus, and the West Nile virus (WNV), should be considered when making a diagnosis.

Amyotrophic Lateral Sclerosis Market Key Facts
• The United States accounts for the largest Amyotrophic Lateral Sclerosis market size compared to EU-4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan.
• In the United States, the Amyotrophic Lateral Sclerosis market size is anticipated to rise from USD 369 million in 2021 during the forecast period.
• Among the EU-4 countries, Germany had the largest Amyotrophic Lateral Sclerosis market size (USD 3 million) in 2021, while Spain had the smallest with USD 2 million.
• Estimates show that the highest cases of Amyotrophic Lateral Sclerosis in the 7MM were in the United States, followed by EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan in the year 2021.
• The US, in 2021 accounted for approximately 25,800+ diagnosed prevalent cases of Amyotrophic Lateral Sclerosis.
• Among the EU-4 and the United Kingdom countries in 2021, Germany had the highest diagnosed prevalent cases of Amyotrophic Lateral Sclerosis with 5,300+ cases, followed by the UK (4,500+) and Italy (4,400+). In contrast, Spain had the lowest cases (3,200+) in 2021.
• Current Amyotrophic Lateral Sclerosis Market dynamics are dominated by the use of RILUTEK, TIGLUTIK, EXSERVAN, NEUDEXTA, RADICAVA, RADICAVA ORS, RELYVRIO, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc).
• As per DelveInsight, the Amyotrophic Lateral Sclerosis Market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.
• The therapies with the potential to get launched in the forecast period include Tofersen, ION363, NurOwn, Masitinib, and others. The launch of these therapies may increase market size in the coming years, assisted by an increasing patient pool of Amyotrophic Lateral Sclerosis patients.

Get a Detailed Overview of the Evolving Amyotrophic Lateral Sclerosis Market Trends @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Amyotrophic Lateral Sclerosis therapies in the market. It also provides a detailed assessment of the Amyotrophic Lateral Sclerosis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Amyotrophic Lateral Sclerosis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Amyotrophic Lateral Sclerosis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Amyotrophic Lateral Sclerosis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Amyotrophic Lateral Sclerosis Epidemiology Segmented as -
• Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Gender-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Age-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Type-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Mutation-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]
• Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the 7MM [2019-2032]

Get Key Insights Into the Evolving Amyotrophic Lateral Sclerosis Epidemiology Trends @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to be launched during the study period. The analysis covers the market share by Amyotrophic Lateral Sclerosis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Amyotrophic Lateral Sclerosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Amyotrophic Lateral Sclerosis Market @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis Therapeutics Assessment
Currently, there is no cure for Amyotrophic Lateral Sclerosis and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of Amyotrophic Lateral Sclerosis includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. Moreover, there are five drugs approved by the US FDA to treat Amyotrophic Lateral Sclerosis, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK.

Medications are also prescribed to help manage symptoms of Amyotrophic Lateral Sclerosis, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar effect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation.

To further improve the treatment outlook, companies across the globe are thoroughly working toward the development of new treatment therapies for Amyotrophic Lateral Sclerosis. Some of the key players in the therapeutic market of Amyotrophic Lateral Sclerosis at a global level are Cytokinetics, Orphazyme, Orion, Brainstorm Cell Therapeutics, Biogen, AB Science, Ionis Pharmaceuticals, Clene Nanomedicine, Immunity Pharma, MediciNova, Biohaven Pharmaceuticals, and others.

Leading Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market Include
Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and many others.

Emerging and Marketed Amyotrophic Lateral Sclerosis Therapies Covered in the Report Include
• Tofersen: Biogen/Ionis Pharmaceuticals
• RNS60: Revalesio Corporation
• ANX005: Annexon
• Masitinib: AB Science
• NurOwn: Brainstorm-Cell Therapeutics
• Gold Nanocrystals/CNM-Au8: Clene Nanomedicine
• Verdiperstat: Biohaven Pharmaceuticals
And Many Others

Learn More About the Emerging Therapies and key Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis Background and Overview
6. Amyotrophic Lateral Sclerosis Patient Journey
7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population
8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment
11. Amyotrophic Lateral Sclerosis Marketed Products
12. Amyotrophic Lateral Sclerosis Emerging Therapies
13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis Market Outlook (7 major markets)
16. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview
17. KOL Views on the Amyotrophic Lateral Sclerosis Market.
18. Amyotrophic Lateral Sclerosis Market Drivers
19. Amyotrophic Lateral Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.